Invitae Co. (NYSE:NVTA – Get Rating) COO Kenneth D. Knight sold 28,295 shares of the company’s stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $3.81, for a total value of $107,803.95. Following the completion of the transaction, the chief operating officer now directly owns 518,895 shares of the company’s stock, valued at $1,976,989.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NVTA stock traded up $0.28 during trading hours on Thursday, hitting $3.72. The stock had a trading volume of 13,400,608 shares, compared to its average volume of 6,823,376. The firm has a market capitalization of $852.96 million, a PE ratio of -1.14 and a beta of 1.89. Invitae Co. has a twelve month low of $3.32 and a twelve month high of $35.51. The stock’s 50 day moving average is $6.45 and its 200 day moving average is $11.77. The company has a debt-to-equity ratio of 0.56, a current ratio of 6.14 and a quick ratio of 5.88.
Invitae (NYSE:NVTA – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical research company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.02). The firm had revenue of $123.70 million during the quarter, compared to analyst estimates of $129.31 million. Invitae had a negative net margin of 148.62% and a negative return on equity of 24.48%. Invitae’s revenue was up 19.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.63) earnings per share. As a group, equities analysts predict that Invitae Co. will post -2.95 earnings per share for the current year.
A number of brokerages recently issued reports on NVTA. Raymond James lowered their price target on Invitae from $10.50 to $8.50 in a report on Wednesday, May 4th. SVB Leerink lowered their price target on Invitae from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Zacks Investment Research downgraded Invitae from a “buy” rating to a “hold” rating in a report on Friday, February 18th. The Goldman Sachs Group lowered their price target on Invitae from $14.00 to $10.00 and set a “neutral” rating for the company in a report on Tuesday, April 19th. Finally, Morgan Stanley lowered their price target on Invitae from $37.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, February 15th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.07.
Invitae Company Profile (Get Rating)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.